Supported by:

Russian biotech company opens office in Munich to expand international operations

Data Matrix, a Russian provider of software, data management and biostatistics services for clinical trials, has opened an office in Munich and joined the Bavarian biotech cluster

Jul 26, 2017
The move will allow the St. Petersburg-based company to expand its activities and launch its newest products on the European market. Data Matrix also hopes to find partners among the resident companies of the Bavarian cluster.

"Our growth and experience with international companies [from the EU and the US] has convinced us to launch in Europe. We chose Munich as the heart of European biotech," stated Data Matrix CEO Ivan Dobromyslov.

The company has been working with clinical data since 2009. Its software applications have been designed in accordance with international clinical data interchange standards to automate the processes of clinical trials, with users managing and monitoring online the ongoing trials.

Data Matrix claims to have conducted 139 projects with pharmaceutical and biotech companies and CROs so far, allowing some of its clients to reduce their R&D costs by 15%.

At the end of last year, Data MATRIX raised 160 million rubles (roughly $2.1 million at that time’s exchange rate) from Russian venture funds IIDF (FRII) and Primer Capital.